We all were fortunate to have Dr. Joe Selby, Executive Director of the Patient-Centered Outcomes Research Institute (PCORI), visit Duke and spend time with fellows and faculty alike. He sat down for a friendly, informal conversation with fellows on Monday for lunch, then gave Grand Rounds on the future of comparative effectiveness research and how PCORI will play an integral role. Finally he also gave the DCRI Grand rounds last week, talking about exciting changes to clinical research in the future.
Author Archives: matthew.sherwood
Darren McGuire gives Grand Rounds, discusses diabetes and cardiovascular research with Weng Wong
Weng Wong, DCRI Research Fellow, discusses with Darren McGuire, Associate professor of Medicine at UT Southwestern, his clinical research training as a DCRI fellow, future of cardiovascular research on diabetic agents and the future of regulation from the FDA.
Darren McGuire also gave an excellent Grand Rounds on cardiovascular research in diabetes, the impact of diabetes on the US population, new oral therapies, and FDA regulation of these agents, and those coming in the future.
CT surgeon Jacob Schroder gives Cardiology Grand Rounds on ECMO at Duke
Dr. Jacob Schroder, Duke’s newest CT surgery faculty member, gives a great Grand Rounds on ECMO at Duke and the initiation of an official ECMO program.
Attached are references that might add to his excellent presentation:
Dr. Clyde Yancy discusses mentorship, gives Cardiology Grand Rounds
Prateeti Khazanie, Duke Cardiology fellow, interviews the engaging Clyde Yancy, Chief of Cardiology at Northwestern, about how a fellow develops a mentor relationship, and finding the right person to work with.
Duke cardiology fellows and faculty were privileged to have Clyde Yancy as this year’s visiting professor, and he did not disappoint, delivering an excellent grand rounds on the present and future creation of national guidelines, both how and who they are made for.
Duke Cardiology Grand Rounds: James Tulsky and Joe Rogers discuss Palliative Care in CHF
Dr. James Tulsky, Chief of Palliative Care at Duke, discusses how palliative care is so integral to the care of advanced CHF patients, but perhaps underutilized. Dr. Joseph Rogers, Vice Chief of Clinical Services for Duke Cardiology, then describes the PAL-HF study, pertinent background, and its inception with the NIH.
Gwen Bernacki discusses the new ACC Geriatric Council
Matt Sherwood, DCRI fellow, talks to Gwen Bernacki, cofellow at DCRI, about the newly formed ACC geriatric Council. Gwen enumerates their mission, and how participation as the Fellow-in-training representative to the council has been a privilege she much enjoys during her fellowship.
ASTRONAUT fails to launch, Aliskiren has neutral effect in acute CHF trial
Rob Mentz, Duke Cardiology fellow, interviews Dr. Mihai Gheorghiade, PI of the ASTRONAUT trial on aliskiren therapy in acute heart failure patients. Also, there was a question of safety in patients with diabetes taking ACEi/ARB. What is the future for aliskiren, given these results?
Talking to Rob Califf about embargo and open access journals for freedom of information
Duke Cardiology fellow Matt Sherwood interviews Dr. Rob Califf, professor of Medicine and Director of the DTMI, on what embargo restrictions mean, whether they help clinicians, and the concept of open access journals. As Rob Califf would say “The data just wants to be free.”
STREAM trial discussion with Paul Armstrong
Akshay Bagai, DCRI chief fellow, interview Dr. Paul Armstrong co-PI of the STREAM trial, which evaluated the strategy of early fibrinolytic therapy in patients that are distant to a primary PCI hospital and then mandatory cardiac catheterization. This pharmacoinvasive strategy was shown to be as effective as primary PCI, and is an important option for patients that are diagnosed far away from a primary PCI center.
TERISA trial: Ranolazine works for angina, but so does placebo
Duke Cardiology fellow Matt Sherwood interviews Darren McGuire, Associate professor at UTSW and investigator on the TERISA trial on the recent findings presented this morning. Ranolazine had a benefit in reducing anginal symptoms in diabetic patients, but the placebo effect, seen in both arms, was much larger than expected. Also, they discuss geographical variation and clinical role of ranolazine in the future.